Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma

NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer?

Maintenance pembrolizumab vs placebo for metastatic urothelial cancer

SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for muscle-invasive bladder cancer

Genetic testing and PARP inhibitors in metastatic prostate cancer

Metastatic castration resistant prostate cancer: Updates from ASCO 2019

Highlights from ASCO 2019

Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer

New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer

Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer with focus on intermediate IMDC-risk population

Enzalutamide as treatment for men with mHSPC who have received testosterone suppression